Listen to this article on the DDW Podcast: Matt Hill, Founder and CEO of Elegen writes about the importance of innovation in DNA synthesis to address critical bottlenecks in biotherapy development. With advanced technology and a growing understanding of the underlying biology, biotherapy development has evolved. Since 2010, investments in the field have grown and the […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!